PUBLIC COMPANY
save$CMPSCOMPASS Pathways plc
$CMPS8.1200+1.75%Chesire, GBupdated 2h ago
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
7
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
🐶 Hiring Signal
News
- Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depressionHelus Pharma's psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious a…biospace · 2d ago
- Helus' chemically modified psychedelic hits key goals in phase 3 depression trialHelus Pharma's oral chemically modified version of psilocybin hit the key goals of a phase 3 study as an adjunctive treatment in major depressive disorder.fiercebiotech · 3d ago
- HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s DayIbogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.biospace · 5d ago
- FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on OvertonIn advance of a Senate vote on Heidi Overton as the next FDA commissioner, the agency has shelved the Commissioner's National Priority Voucher program introduced by former leader Marty Makary, Reut…biospace · 6d ago
- ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veteransThe U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).fiercebiotech · 6d ago
- AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warningThe deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.biopharma_dive · 7d ago
- Delix raises $100M to advance at-home psychedelic without hallucinogenic effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 8d ago
- Delix raises $100M to advance at-home psychedelic without hallucinatory effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.biospace · 8d ago
- Heron sells assets to CorMedix for $145M upfront; Faeth's stock tumblesPlus, news about Immunovant, Abeona Therapeutics, Ellodi Pharmaceuticals, Spruce Biosciences, Adrenyx Biosciences, Edesa Biotech, Kyorin Pharmaceutical, Charles River Laboratories, Frontage, Compas…endpoints · 9d ago
- Update: Compass submits psilocybin depression drug for approval after stock wobblesCompass Pathways has completed an FDA filing for COMP360, with an expected launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilo…biospace · 9d ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that